Document is current
Any future updates will be listed below
-
Authors
Taylor, Katherine J. https://orcid.org/0000-0003-0768-5789
Singer, Susanne https://orcid.org/0000-0001-5784-7964
Langemeijer, Saskia
Kelly, Richard J. https://orcid.org/0000-0002-3318-9482
Arnold, Louise
Panse, Jens https://orcid.org/0000-0001-6316-3112
Patriquin, Christopher J. https://orcid.org/0000-0002-2089-8650
Nishimura, Jun-ichi
Piggin, Maria
Burmester, Pascale O
-
Funding
Funding for this research was provided by:
International PNH Interest Group
- License Information
-
More Information
Article History
Received: 24 February 2025
Accepted: 16 April 2025
First Online: 29 April 2025
Declarations
:
: Absolutely no identifying/personal information was collected in this study and the limited responses are anonymous. Therefore this was not applicable.
: S. S.– Honoraria from Lilly for reviews of their Quality-of-Life-Award, outside of this study.R.J.K.– Research funding (to institute) from Sobi and Novartis, speakers bureau from Alexion, Sobi, Novartis, Otsuka, consultancy from Alexion, Otsuka, Omeros, Roche, Sobi, Novartis and Florio.L.A.– Speaker honoraria from Alexion, Sobi, Novartis. Consultancy for Alexion, Amgen, Florio.J.P.– Consulting fees from Alexion, Sobi, Omeros, Sandoz. Payment or honoraria for lectures, presentations, advisory boards, speakers bureaus, manuscript writing or educational events from Alexion, Amgen, Apellis, AstraZeneca, Blueprint Medicines, BMS, Boehringer Ingelheim, Novartis, Pfizer, Roche, Samsung Bioepis, Sanofi, SobiC.J.P.– Speaking honoraria from Alexion, Amgen, Sobi, Novartis. Consultancy for Alexion, Amgen, Apellis, BioCryst, Novartis, Regeneron, Roche, Sanofi, Takeda. J.N.– Consultancy for Alexion, Roche, Chugai, Novartis, Sobi, Asahikasei.
